AR116428A1 - Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo - Google Patents

Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo

Info

Publication number
AR116428A1
AR116428A1 ARP190102645A ARP190102645A AR116428A1 AR 116428 A1 AR116428 A1 AR 116428A1 AR P190102645 A ARP190102645 A AR P190102645A AR P190102645 A ARP190102645 A AR P190102645A AR 116428 A1 AR116428 A1 AR 116428A1
Authority
AR
Argentina
Prior art keywords
methylbenzo
ilo
thiazol
fluoro
compounds
Prior art date
Application number
ARP190102645A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR116428A1 publication Critical patent/AR116428A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ARP190102645A 2018-09-26 2019-09-18 Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo AR116428A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862736588P 2018-09-26 2018-09-26

Publications (1)

Publication Number Publication Date
AR116428A1 true AR116428A1 (es) 2021-05-05

Family

ID=68085016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102645A AR116428A1 (es) 2018-09-26 2019-09-18 Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo

Country Status (8)

Country Link
US (2) US10752632B2 (cg-RX-API-DMAC7.html)
EP (1) EP3856739A1 (cg-RX-API-DMAC7.html)
JP (2) JP7081047B2 (cg-RX-API-DMAC7.html)
CN (1) CN112955446B (cg-RX-API-DMAC7.html)
AR (1) AR116428A1 (cg-RX-API-DMAC7.html)
CA (1) CA3113968C (cg-RX-API-DMAC7.html)
TW (1) TWI716107B (cg-RX-API-DMAC7.html)
WO (1) WO2020068530A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI716107B (zh) * 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
WO2024081775A1 (en) 2022-10-14 2024-04-18 Eli Lilly And Company Synthesis of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2014159234A1 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
MX381417B (es) * 2014-08-28 2025-03-12 Asceneuron Sa Inhibidores de glucosidasa.
WO2017071636A1 (zh) 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
WO2017106254A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
FR3046053B1 (fr) 2015-12-24 2017-12-22 Sagem Defense Securite Module de pied pour une structure d'exosquelette
CN108884077A (zh) * 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
EP3555094A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Bicyclic oga inhibitor compounds
EP3555087A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
AR111693A1 (es) 2017-05-25 2019-08-07 Lilly Co Eli Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物

Also Published As

Publication number Publication date
JP7560511B2 (ja) 2024-10-02
US10836773B1 (en) 2020-11-17
CA3113968A1 (en) 2020-04-02
CN112955446B (zh) 2024-07-12
JP7081047B2 (ja) 2022-06-06
CA3113968C (en) 2023-08-01
CN112955446A (zh) 2021-06-11
WO2020068530A1 (en) 2020-04-02
US10752632B2 (en) 2020-08-25
TW202026293A (zh) 2020-07-16
EP3856739A1 (en) 2021-08-04
JP2022502389A (ja) 2022-01-11
US20200354370A1 (en) 2020-11-12
JP2022116171A (ja) 2022-08-09
TWI716107B (zh) 2021-01-11
US20200095254A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
ECSP24026637A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona
AR115949A1 (es) Compuestos heterocíclicos
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
AR119672A1 (es) Inhibidor de 15-pgdh
AR121226A1 (es) Compuestos y usos de estos
AR114803A1 (es) Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
AR109349A1 (es) Compuestos y usos
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MX2025008591A (es) Inhibidores de cdk
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
DOP2024000077A (es) Compuestos de cd73
AR114467A1 (es) Moduladores alostéricos positivos del receptor de dopamina d1
MX2020003383A (es) Compuesto de griseofulvina y uso farmacéutico de este.
CL2022001353A1 (es) Inhibidores de egfr
MX2020000576A (es) Compuestos quimicos.
MX2024003130A (es) Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma.
CL2023001440A1 (es) Nuevos derivados de indazol acetileno
MX2023015440A (es) Compuesto de sulfoximina y uso del mismo.
PH12021552953A1 (en) Tricyclic compounds
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR118141A1 (es) Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau
AR110770A1 (es) Moduladores del canal de potasio
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.